Venus Remedies has expanded the reach of its oncology drugs in the Asia Commonwealth of Independent States (CIS) region with marketing authorisations from Ukraine for three cancer drugs -- paclitaxel, oxaliplatin and irinotecan. Its total volume of exports to Ukraine stands at $2.20 million. By strengthening its product portfolio in Ukraine, the company aims to increase this figure by 20 per cent in the next one year. The company is awaiting approval from Ukraine on another 10 applications for marketing authorisations.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
